✦ LIBER ✦

Adjuvant immunotherapy with interleukin 2 and lymphokine-activated killer cells after noncurative resection of primary lung cancer

Book ID: 122392943
Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 138 KB
Volume: 13
Category: Article
ISSN: 0169-5002
DOI: 10.1016/0169-5002(96)84313-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adjuvant immunotherapy with interleukin

✍ Kimura, Hideki; Yamaguchi, Yutaka 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 824 KB

A Phase III randomized study of interleu

A Phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma

✍ Hideki Kimura; Yutaka Yamaguchi 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB 👁 2 views

## Background: Adoptive immunotherapy with interleukin-2 (il-2) and lymphokine-activated killer (lak) cells has resulted in response among some patients with advanced malignant disease. however, the relative therapeutic benefit of adoptive immunotherapy as an adjuvant to surgery has not been determ

A regimen of surgical adjuvant immunothe

A regimen of surgical adjuvant immunotherapy for cancer with interleukin 2 and lymphokine-activated killer cells

✍ Tokujiro Yano; Teruyoshi Ishida; Ichiro Yoshino; Mitsuhiro Murata; Kosei Yasumot 📂 Article 📅 1991 🏛 Springer 🌐 English ⚖ 670 KB

Randomized controlled study with Interle

Randomized controlled study with Interleukin 2 and Lymphokine activated killer (LAK) cells against postoperative primary lung cancer patients

📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 135 KB

The requirements for successful immunoth

The requirements for successful immunotherapy of intraperitoneal cancer using interleukin-2 and lymphokine-activated killer cells

✍ Reyer T. Ottow; Alexander M. M. Eggermont; E. Philip Steller; Paul H. Sugarbaker 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 907 KB

In a significant proportion of patients with gastrointestinal and ovarian malignancy the peritoneal cavity is a prominent site at which surgical treatment fails. Adjuvant treatments directed at this site should be investigated in an attempt to improve survival in patients with these cancers. In the

Immunotherapy of intraperitoneal cancer

Immunotherapy of intraperitoneal cancer with interleukin 2 and lymphokine-activated killer cells reduces tumor load and prolongs survival in murine models

✍ Reyer T. Ottow; E.Philip Steller; Paul H. Sugarbaker; Robert A. Wesley; Steven A 📂 Article 📅 1987 🏛 Elsevier Science 🌐 English ⚖ 778 KB